CDK2

Fig 1. Cell cycle

• CDK2 is a member of a large family of protein kinases that initiates the principal transitions of the eukaryotic cell cycle.
• Mutations in the CDKs and/or their inhibitors is associated with several forms of cancer
• Several research groups, include biotech companies, are discovering to design potential drugs for cancer
• Cyclin-dependent kinases are important drug target for cancer therapy

A
1	2	3

B

Fig 2. CDK2 binding mode

Inhibitors in Clinical Trials

Company	Drug	Indication	Target kinase	Status
Roche	Flavopiridol	Solid tumors	CDK4	Phase 2
SUGEN	SU-9516	Solid tumors	CDK2	Preclinical
Glaxo	GW-8510	Solid tumors	CDK2	Preclinical
Onyx	PD-0183812	Solid tumors	CDK4	Preclinical